Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trial.
Juan Pablo FriasGuillermo Gonzalez-GalvezEva JohnssonJill MaaskeMarcia A TestaDonald C SimonsonNalina DronamrajuRicardo Garcia-SanchezAnne L PetersPublished in: Diabetes, obesity & metabolism (2020)
Compared with GLIM, concurrent addition of DAPA + SAXA significantly improved glycaemic control, body weight and other metabolic parameters in patients inadequately controlled on metformin. Trial: NCT02419612, ClinicalTrials.gov.
Keyphrases
- type diabetes
- body weight
- double blind
- phase iii
- end stage renal disease
- open label
- study protocol
- placebo controlled
- phase ii
- ejection fraction
- clinical trial
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- cardiovascular disease
- randomized controlled trial
- squamous cell carcinoma
- radiation therapy
- bone marrow
- adipose tissue
- mesenchymal stem cells
- locally advanced
- rectal cancer